Survey Finds Two-Thirds of Leading Pharmas Restrict ChatGPT Usage, While Many in Life Sciences Industry Deem AI ‘Overrated’

In the ongoing debate over the integration of artificial intelligence (AI) into various industries, the biopharmaceutical sector is taking a cautious approach. According to a recent survey conducted by ZoomRx among over 200 professionals in life sciences, more than half reported that their companies have prohibited the use of OpenAI’s ChatGPT tool. 

This ban was particularly prevalent among the top 20 pharmaceutical companies, with 65% implementing it. Concerns about potential leaks of sensitive internal data to competitors drove these policies.

Andrew Yukawa, a product manager at ZoomRx, emphasized the delicate balance between the speculative benefits and recognized security risks associated with AI implementation in life sciences. He highlighted a past incident where a bug in ChatGPT led to a temporary shutdown, allowing some users to access others’ chat history. This raised concerns that proprietary information could inadvertently become part of OpenAI’s training dataset.

Despite the prevalence of bans, the survey revealed a lack of proactive measures beyond restrictions. Less than 60% of companies provided training or guidelines on the safe use of ChatGPT, though some indicated plans to do so in the future.

Nevertheless, despite the reservations and bans, many professionals in the life sciences sector are actively using ChatGPT. Over ha

[…]
Content was cut in order to protect the source.Please visit the source for the rest of the article.